Plasma filtration for the controlled removal of liposomal therapeutics - From the apheretic site of view

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F17%3A10365938" target="_blank" >RIV/00179906:_____/17:10365938 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11150/17:10365938

Výsledek na webu

<a href="http://www.sciencedirect.com/science/article/pii/S1567568817300648?via%3Dihub" target="_blank" >http://www.sciencedirect.com/science/article/pii/S1567568817300648?via%3Dihub</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.022" target="_blank" >10.1016/j.atherosclerosissup.2017.05.022</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Plasma filtration for the controlled removal of liposomal therapeutics - From the apheretic site of view

Popis výsledku v původním jazyce

Introduction: Nanoparticle-based drug delivery systems can overcome the dose-limited toxicity of cytostatics. Pegylated doxorubicin-containing liposomes (PLD) are able to reduce cardiotoxicity. PLD quickly (in 2 days) attains therapeutic concentration in tumorous tissue (kinetic targeting), while its distribution in normal tissue, which is a cause of mucocutaneous toxicity (MCT), is delayed. We examined PLD extracorporeal removal effectivity, using plasma filtration (PF) to determine whether the drug could be withheld prior to its organ distribution responsible for MCT toxicity. Methods: Nine patients suffering from platinum-resistant ovarian cancer were treated with a infusion of 50 mg/m(2) of PLD/cycle - for four cycles q4w. Over 44 (46)-47 (49) hours postinfusion, the patients (14 cycles in total) underwent PF using the cascade method. Doxorubicin blood concentration was monitored by the HPLC method during 116 h. Individual pharmacokinetic parameters of doxorubicin were estimated. Results: Over 44 (46) -47 (49) hours postinfusion, a single one-volume plasma filtration removed 35 (22-45)% of the remaining doxorubicin amount in the body. Symptoms of MCT - PPE-like syndrome (grade 3) appeared in one patient. Only one adverse reaction (1/14-7%) - short-term malaise and nausea - was reported as being related to PF. Conclusion: PF does remove a clinically important amount of doxorubicin in a kinetic targeting approach, which can be a useful tool for the increased efficacy and tolerability of therapy with PLD. There were no serious signs of drug toxicity and/or PF-related adverse events.

Název v anglickém jazyce

Plasma filtration for the controlled removal of liposomal therapeutics - From the apheretic site of view

Popis výsledku anglicky

Introduction: Nanoparticle-based drug delivery systems can overcome the dose-limited toxicity of cytostatics. Pegylated doxorubicin-containing liposomes (PLD) are able to reduce cardiotoxicity. PLD quickly (in 2 days) attains therapeutic concentration in tumorous tissue (kinetic targeting), while its distribution in normal tissue, which is a cause of mucocutaneous toxicity (MCT), is delayed. We examined PLD extracorporeal removal effectivity, using plasma filtration (PF) to determine whether the drug could be withheld prior to its organ distribution responsible for MCT toxicity. Methods: Nine patients suffering from platinum-resistant ovarian cancer were treated with a infusion of 50 mg/m(2) of PLD/cycle - for four cycles q4w. Over 44 (46)-47 (49) hours postinfusion, the patients (14 cycles in total) underwent PF using the cascade method. Doxorubicin blood concentration was monitored by the HPLC method during 116 h. Individual pharmacokinetic parameters of doxorubicin were estimated. Results: Over 44 (46) -47 (49) hours postinfusion, a single one-volume plasma filtration removed 35 (22-45)% of the remaining doxorubicin amount in the body. Symptoms of MCT - PPE-like syndrome (grade 3) appeared in one patient. Only one adverse reaction (1/14-7%) - short-term malaise and nausea - was reported as being related to PF. Conclusion: PF does remove a clinically important amount of doxorubicin in a kinetic targeting approach, which can be a useful tool for the increased efficacy and tolerability of therapy with PLD. There were no serious signs of drug toxicity and/or PF-related adverse events.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

<a href="/cs/project/NV16-30366A" target="_blank" >NV16-30366A: Lipozomy (drug delivery systems) v kineticky řízené léčbě platinarezistentního karcinomu ovarií doxorubicinem pomocí plazmafiltrace.</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Atherosclerosis, Supplements

ISSN

1567-5688

e-ISSN

—

Svazek periodika

30

Číslo periodika v rámci svazku

November

Stát vydavatele periodika

IE - Irsko

Počet stran výsledku

8

Strana od-do

286-293

Kód UT WoS článku

000415625000042

EID výsledku v databázi Scopus

2-s2.0-85032454029